title: A combination of bisphosphonate and BMP additives in impacted bone allografts.
abstract: OP-1 increases bone ingrowth distance of new bone into allografts (Tägil et al. 2000), but the bone density after incorporation may be reduced by an increase in resorption (Höistner et al. 2000). Bisphosphonates inactivate osteoclasts and can be used to increase allograft bone density after incorporation (Aspenberg and Astrand 2002). A combination of locally-applied bisphosphonate and OP-1 in the graft could therefore be expected to increase both new bone ingrowth and density. We tested this by using a rat bone chamber model. OP-1 alone increased the ingrowth distance of bone. Clodronate increased final bone density greatly, but reduced the ingrowth distance of new bone into grafts that were extremely impacted. This reduction was improved by adding OP-1. Regardless of graft density, combinations of OP-1 and clodronate included a high final bone density, but the ingrowth distances were shorter than with OP-1 alone. These data indicate that new bone and tissue ingrowth into a compacted graft depends on resorption and that resorption is a prerequisite for the stimulating effect of OP-1 in this experimental set-up. Although the problems associated with the use of OP-1 in impaction grafting may be solved by adding a bisphosphonate, some of the benefits of OP-1 can be lost.
authors.affiliation: Department of Orthopedics, Lund University Hospital, Lund, Sweden. charlotte.jeppsson@ort.lu.se
authors.forename: Charlotte
authors.initials: C
authors.lastname: Jeppsson
authors.forename: Jörgen
authors.initials: J
authors.lastname: Astrand
authors.forename: Magnus
authors.initials: M
authors.lastname: Tägil
authors.forename: Per
authors.initials: P
authors.lastname: Aspenberg
mesh_terms: D000818:Animals; D015519:Bone Density / Q000502:physiology; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D016025:Bone Transplantation / Q000379:methods*; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D008297:Male; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012680:Sensitivity and Specificity; D014184:Transplantation, Homologous
chemical_list: D019485:Bone Morphogenetic Proteins; D004164:Diphosphonates